NASDAQ:CALA

Calithera Biosciences Stock Forecast, Price & News

$2.28
-0.04 (-1.72 %)
(As of 06/11/2021 12:00 AM ET)
Add
Compare
Today's Range
$2.25
$2.36
50-Day Range
$1.96
$2.50
52-Week Range
$1.87
$6.18
Volume721,302 shs
Average Volume1.12 million shs
Market Capitalization$168.83 million
P/E RatioN/A
Dividend YieldN/A
Beta1.67
30 days | 90 days | 365 days | Advanced Chart
Receive CALA News and Ratings via Email

Sign-up to receive the latest news and ratings for Calithera Biosciences and its competitors with MarketBeat's FREE daily newsletter.


Calithera Biosciences logo

About Calithera Biosciences

Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase II clinical trial to treat solid tumors. The company also offers INCB001158, an oral inhibitor of arginase that is in Phase I/II clinical trial for the treatment of hematology and oncology. The company is also developing CB-280, an oral arginase inhibitor that is in Phase 1b clinical trial for the treatment of cystic fibrosis and chronic airway infection; and CB-708, an orally administered small molecule inhibitor of CD73, as well as CB-668, an inhibitor of the enzyme IL4I1. It has a license agreement with Mars, Inc. to develop and commercialize Symbioscience's portfolio of arginase inhibitors for use in human healthcare. The company also has clinical trial collaboration with Pfizer to evaluate Pfizer's PARP inhibitor talazoparib and CDK4/6 inhibitor palbociclib, each in combination with telaglenasta. In addition, it has a collaboration and license agreement with Incyte Corporation for the research, development, and commercialization of INCB001158, a small molecule arginase inhibitor for the treatment of hematology and oncology; and a license agreement with Antengene Corporation Ltd. for the development and commercialization of CB-708. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.67 out of 5 stars

Medical Sector

359th out of 2,099 stocks

Pharmaceutical Preparations Industry

166th out of 831 stocks

Analyst Opinion: 3.3Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Calithera Biosciences (NASDAQ:CALA) Frequently Asked Questions

Is Calithera Biosciences a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Calithera Biosciences in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Calithera Biosciences stock.
View analyst ratings for Calithera Biosciences
or view top-rated stocks.

What stocks does MarketBeat like better than Calithera Biosciences?

Wall Street analysts have given Calithera Biosciences a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Calithera Biosciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Calithera Biosciences?

Calithera Biosciences saw a increase in short interest in the month of May. As of May 14th, there was short interest totaling 3,210,000 shares, an increase of 23.9% from the April 29th total of 2,590,000 shares. Based on an average daily trading volume, of 949,700 shares, the short-interest ratio is currently 3.4 days.
View Calithera Biosciences' Short Interest
.

When is Calithera Biosciences' next earnings date?

Calithera Biosciences is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Calithera Biosciences
.

How were Calithera Biosciences' earnings last quarter?

Calithera Biosciences, Inc. (NASDAQ:CALA) released its earnings results on Thursday, May, 6th. The biotechnology company reported ($0.28) earnings per share for the quarter, missing analysts' consensus estimates of ($0.27) by $0.01.
View Calithera Biosciences' earnings history
.

How has Calithera Biosciences' stock been impacted by Coronavirus (COVID-19)?

Calithera Biosciences' stock was trading at $5.23 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CALA stock has decreased by 56.4% and is now trading at $2.28.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for CALA?

2 analysts have issued 1 year price objectives for Calithera Biosciences' shares. Their forecasts range from $2.00 to $5.00. On average, they expect Calithera Biosciences' stock price to reach $4.00 in the next year. This suggests a possible upside of 75.4% from the stock's current price.
View analysts' price targets for Calithera Biosciences
or view top-rated stocks among Wall Street analysts.

Who are Calithera Biosciences' key executives?

Calithera Biosciences' management team includes the following people:
  • Dr. Susan M. Molineaux, Founder, CEO, Pres & Director (Age 67, Pay $806.95k)
  • Dr. Keith Orford, Chief Medical Officer (Age 49, Pay $629.03k)
  • Ms. Stephanie Wong, CFO & Sec. (Age 47)
  • Ms. Sumita Ray, Sr. VP, Gen. Counsel & Chief Compliance Officer (Age 47)
  • Dr. Eric B. Sjogren, Sr. VP of Drug Discovery (Age 64)
  • Dr. Christopher J. Molineaux, Sr. VP of Devel. (Age 68)
  • Mr. Frank Parlati, Sr. VP of Research (Age 52)

Who are some of Calithera Biosciences' key competitors?

What other stocks do shareholders of Calithera Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Calithera Biosciences investors own include Puma Biotechnology (PBYI), Incyte (INCY), BioMarin Pharmaceutical (BMRN), (MDVN) (MDVN), Celadon Group (CGI), Dynavax Technologies (DVAX), Rigel Pharmaceuticals (RIGL), First Solar (FSLR), Plug Power (PLUG) and Sorrento Therapeutics (SRNE).

What is Calithera Biosciences' stock symbol?

Calithera Biosciences trades on the NASDAQ under the ticker symbol "CALA."

Who are Calithera Biosciences' major shareholders?

Calithera Biosciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include Primecap Management Co. CA (13.96%), Federated Hermes Inc. (9.00%), BlackRock Inc. (8.74%), BVF Inc. IL (7.52%), Dimensional Fund Advisors LP (1.94%) and Geode Capital Management LLC (1.55%). Company insiders that own Calithera Biosciences stock include Bvf Partners L P/Il, Keith Orford, Stephanie Wong, Susan Molineaux and Value Fund L P Biotechnology.
View institutional ownership trends for Calithera Biosciences
.

Which institutional investors are selling Calithera Biosciences stock?

CALA stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Federated Hermes Inc., Silverarc Capital Management LLC, AQR Capital Management LLC, Northern Trust Corp, Dimensional Fund Advisors LP, D. E. Shaw & Co. Inc., and Credit Suisse AG.
View insider buying and selling activity for Calithera Biosciences
or view top insider-selling stocks.

Which institutional investors are buying Calithera Biosciences stock?

CALA stock was acquired by a variety of institutional investors in the last quarter, including BVF Inc. IL, Altium Capital Management LP, BlackRock Inc., Axiom Investment Management LLC, Renaissance Technologies LLC, Millennium Management LLC, TSP Capital Management Group LLC, and Geode Capital Management LLC. Company insiders that have bought Calithera Biosciences stock in the last two years include Bvf Partners L P/Il, Susan Molineaux, and Value Fund L P Biotechnology.
View insider buying and selling activity for Calithera Biosciences
or or view top insider-buying stocks.

How do I buy shares of Calithera Biosciences?

Shares of CALA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Calithera Biosciences' stock price today?

One share of CALA stock can currently be purchased for approximately $2.28.

How much money does Calithera Biosciences make?

Calithera Biosciences has a market capitalization of $168.83 million and generates $22.25 million in revenue each year. The biotechnology company earns $-90,140,000.00 in net income (profit) each year or ($1.31) on an earnings per share basis.

How many employees does Calithera Biosciences have?

Calithera Biosciences employs 92 workers across the globe.

What is Calithera Biosciences' official website?

The official website for Calithera Biosciences is www.calithera.com.

Where are Calithera Biosciences' headquarters?

Calithera Biosciences is headquartered at 343 OYSTER POINT BLVD. SUITE 200, SOUTH SAN FRANCISCO CA, 94080.

How can I contact Calithera Biosciences?

Calithera Biosciences' mailing address is 343 OYSTER POINT BLVD. SUITE 200, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-870-1000 or via email at [email protected]


This page was last updated on 6/13/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.